Analysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $13.76

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been given an average rating of “Hold” by the twenty-one research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, seventeen have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $12.89.

Several equities research analysts recently weighed in on the company. Mizuho dropped their price target on Sage Therapeutics from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. JPMorgan Chase & Co. dropped their price target on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 6th. Royal Bank of Canada lowered Sage Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $10.00 to $4.00 in a research report on Friday, October 4th. Piper Sandler restated an “overweight” rating and set a $26.00 price target (down from $52.00) on shares of Sage Therapeutics in a research report on Wednesday. Finally, Truist Financial dropped their price target on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SAGE. Price T Rowe Associates Inc. MD grew its holdings in shares of Sage Therapeutics by 69.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock worth $15,217,000 after acquiring an additional 333,805 shares during the period. Vanguard Group Inc. grew its holdings in shares of Sage Therapeutics by 8.1% in the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after acquiring an additional 432,013 shares during the period. Virtu Financial LLC bought a new stake in shares of Sage Therapeutics in the first quarter worth $187,000. Bellevue Group AG grew its holdings in shares of Sage Therapeutics by 27.1% in the first quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock worth $83,684,000 after acquiring an additional 952,193 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Sage Therapeutics by 4.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,568 shares of the biopharmaceutical company’s stock worth $723,000 after acquiring an additional 1,693 shares during the period. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Performance

Shares of SAGE stock opened at $6.08 on Tuesday. The firm has a market cap of $365.91 million, a P/E ratio of -0.72 and a beta of 0.91. Sage Therapeutics has a fifty-two week low of $5.84 and a fifty-two week high of $28.26. The business’s 50 day moving average price is $7.48 and its 200-day moving average price is $9.97.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The business had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. Sage Therapeutics’s quarterly revenue was up 337.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.81) earnings per share. As a group, equities analysts predict that Sage Therapeutics will post -6.43 EPS for the current year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.